All In Biotech

Drug Trial Radar · NCT06132958

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 710 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

710

Planned (sponsor's estimate)

Start

Dec 6, 2023

Primary completion

Jan 10, 2028

Study completion Jan 10, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

Conditions

  • Endometrial Cancer

Interventions

  • Sacituzumab tirumotecanBiological

    4 mg/kg of sacituzumab tirumotecan by IV infusion

  • DoxorubicinDrug

    60 mg/m\^2 of doxorubicin by IV Infusion

  • PaclitaxelDrug

    80 mg/m\^2 of paclitaxel by IV infusion

  • Nab-paclitaxelDrug

    100 mg/m\^2 of nab-paclitaxel by IV infusion

  • Rescue medicationsDrug

    Participants will receive the following rescue medications per approved product label before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and steroid mouthwash (dexamethasone or equivalent).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 27 months
  2. Overall Survival (OS)Time frame: Up to approximately 48 months

Locations

242 sites in 31 countries. Site status is shown where the registry gives one.

  • USA Mitchell Cancer Institute ( Site 4142)

    Mobile, Alabama

  • Alaska Womens Cancer Care ( Site 4122)

    Anchorage, Alaska

  • HonorHealth (HH) ( Site 8000)

    Phoenix, Arizona

  • Arizona Oncology Associates - HOPE ( Site 8002)

    Tucson, Arizona

  • UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4131)

    Los Angeles, California

  • California Pacific Medical Center - Van Ness Campus ( Site 4129)

    San Francisco, California

  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 4114)

    New Haven, Connecticut

  • MedStar Washington Hospital Center ( Site 4108)

    Washington D.C., District of Columbia

  • Mount Sinai Cancer Center ( Site 4117)

    Miami Beach, Florida

  • AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 4113)

    Orlando, Florida

  • Florida Cancer Specialists - East ( Site 7000)

    West Palm Beach, Florida

  • Northside Hospital ( Site 4112)

    Atlanta, Georgia

  • Augusta University ( Site 4116)

    Augusta, Georgia

  • Centricity Research Columbus Cancer Center ( Site 4154)

    Columbus, Georgia

  • NorthShore University HealthSystem - Evanston Hospital ( Site 4110)

    Evanston, Illinois

  • Parkview Research Center at Parkview Regional Medical Center ( Site 4132)

    Fort Wayne, Indiana

  • Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 4150)

    Edgewood, Kentucky

  • University Medical Center New Orleans ( Site 4133)

    New Orleans, Louisiana

  • TRIALS 365 ( Site 4105)

    Shreveport, Louisiana

  • University of Massachusetts Memorial Medical Center ( Site 4103)

    Worcester, Massachusetts

  • Washington University School of Medicine-Obstetrics & Gynecology ( Site 4146)

    St Louis, Missouri

  • The Center of Hope ( Site 4109)

    Reno, Nevada

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 4118)

    Hackensack, New Jersey

  • Atlantic Health System Morristown Medical Center ( Site 4135)

    Morristown, New Jersey

  • Holy Name Medical Center ( Site 4115)

    Teaneck, New Jersey

  • New York - Presbyterian Brooklyn Methodist Hospital ( Site 4134)

    Brooklyn, New York

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 4156)

    Mineola, New York

  • Laura and Isaac Perlmutter Cancer Center ( Site 4106)

    New York, New York

  • Icahn School of Medicine at Mount Sinai-Department of Obstetrics, Gynecology, and Reproductive Scie ( Site 4128)

    New York, New York

  • Good Samaritan Hospital Medical Center ( Site 4139)

    West Islip, New York

  • Duke Cancer Institute ( Site 4120)

    Durham, North Carolina

  • Sanford Health Roger Maris Cancer Center ( Site 4158)

    Fargo, North Dakota

  • University of Cincinnati Medical Center ( Site 4136)

    Cincinnati, Ohio

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C (Site 4125)

    Columbus, Ohio

  • Sidney Kimmel Cancer Center - Jefferson Health ( Site 4157)

    Philadelphia, Pennsylvania

  • AHN West Penn Hospital-Gynecologic Oncology ( Site 4111)

    Pittsburgh, Pennsylvania

  • Asplundh Cancer Pavilion ( Site 4107)

    Willow Grove, Pennsylvania

  • Women & Infants Hospital ( Site 4138)

    Providence, Rhode Island

  • Sanford Cancer Center-Gynecologic Oncology ( Site 4121)

    Sioux Falls, South Dakota

  • The West Clinic, PLLC dba West Cancer Center ( Site 4102)

    Germantown, Tennessee

Showing 40 of 242 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.